_256_384.jpg)
News | May 14, 2025
Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’
_256_384.jpg)
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
_256_384.jpg)
Mesalazine is used to treat inflammatory bowel disease
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
Achira is engaged in development and commercialization of PoC medical test kits in India
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
The company has posted net profit of Rs. 4,121.55 crores for the Financial Year ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
